SLC5A2 and chronic kidney disease: Subsequent studies showed that SGLT2 could significantly reduce the risk of CKD progression with diabetic kidney disease (DKD) as well as nondiabetic CKD with the anti-diabetic drug dapagliflozin [150–152].